Visceral Pain – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -
VISCERAL PAIN PIPELINE ANALYSIS
• Visceral pain is a kind of nociceptive pain that evolves out from the internal organs, which results from the activation of nociceptors in pelvic, thoracic, or abdominal viscera organs.
• Nociceptive pain is caused by physical pressure, an injury, or inflammation to the trunk area of the body, including the heart, abdominal part, pelvic organs, and lungs of the body. Symptoms include squeezing, aches, cramps and diffuse pain.
• The treatment of visceral pain includes analgesics, like narcotics and NSAIDs, and pain modifiers including tricyclic antidepressants and anticonvulsants.
• Over the past few years, several types of medications in the market are prescribed for the management of pain as off-label despite its analgesic properties. Due to this, novel targeted drug therapy is going to play an important role in the growing market worldwide.
• However, analgesics are used as the first line of therapy, post a period their effect declines and can cause a quilting effect at any given dosage.
• This category includes the drugs Morphine and codeine, which has high chances of abuse, thus limiting the usage.
• Pain modifiers are expected to witness growth over the projected period, that includes various products like antidepressants that will increase the level of certain brain chemicals including serotonin and dopamine, which help regulate pain signals and improve mood. To treat the chronic soreness, these medications are frequently used in lower doses.
• Antidepressants are usually used for chronic pain, as they will help in relieving sleeping problems and fatigue caused by chronic soreness.
• Irritable bowel syndrome is likely to be the rapidly growing segment. Change in eating habits and lifestyle has resulted in an increase in the occurrence of this disorder, which is expected to drive the demand for therapies that will help in managing the disease. Allergan Inc. has announced the approval of VIBERZI by Health Canada, which helped the patients to overcome irritable bowel syndrome.
• Limited research and development are undertaken on interstitial cystitis condition because of its undetermined pathophysiological mechanism and etiology. Crohn’s disease was the largest indication segment for the visceral pain.
• Some of the pipeline drugs in clinical trial studies such as Lidocaine, Oxycodaine, Morphine, tetrahydrocannabinol, CR845, GIC-1001, Lubiprostone are expected to increase the market growth of visceral pain over the next decade.
• High therapy costs of visceral pain treatment are likely to hamper the growth of the market. However, the costs are expected to reduce due to various factors including intensive research & development of the drugs, production scales, and government grants & subsidies are expected to boost the visceral pain industry.
• The market came to witness significant gain, resulting in an increase in the collaboration within the pharmaceutical companies. Lack of awareness of the visceral pain treatments in the society is going to be a challenge for the growth of the market.
• Visceral pain is a kind of nociceptive pain that evolves out from the internal organs, which results from the activation of nociceptors in pelvic, thoracic, or abdominal viscera organs.
• Nociceptive pain is caused by physical pressure, an injury, or inflammation to the trunk area of the body, including the heart, abdominal part, pelvic organs, and lungs of the body. Symptoms include squeezing, aches, cramps and diffuse pain.
• The treatment of visceral pain includes analgesics, like narcotics and NSAIDs, and pain modifiers including tricyclic antidepressants and anticonvulsants.
• Over the past few years, several types of medications in the market are prescribed for the management of pain as off-label despite its analgesic properties. Due to this, novel targeted drug therapy is going to play an important role in the growing market worldwide.
• However, analgesics are used as the first line of therapy, post a period their effect declines and can cause a quilting effect at any given dosage.
• This category includes the drugs Morphine and codeine, which has high chances of abuse, thus limiting the usage.
• Pain modifiers are expected to witness growth over the projected period, that includes various products like antidepressants that will increase the level of certain brain chemicals including serotonin and dopamine, which help regulate pain signals and improve mood. To treat the chronic soreness, these medications are frequently used in lower doses.
• Antidepressants are usually used for chronic pain, as they will help in relieving sleeping problems and fatigue caused by chronic soreness.
• Irritable bowel syndrome is likely to be the rapidly growing segment. Change in eating habits and lifestyle has resulted in an increase in the occurrence of this disorder, which is expected to drive the demand for therapies that will help in managing the disease. Allergan Inc. has announced the approval of VIBERZI by Health Canada, which helped the patients to overcome irritable bowel syndrome.
• Limited research and development are undertaken on interstitial cystitis condition because of its undetermined pathophysiological mechanism and etiology. Crohn’s disease was the largest indication segment for the visceral pain.
• Some of the pipeline drugs in clinical trial studies such as Lidocaine, Oxycodaine, Morphine, tetrahydrocannabinol, CR845, GIC-1001, Lubiprostone are expected to increase the market growth of visceral pain over the next decade.
• High therapy costs of visceral pain treatment are likely to hamper the growth of the market. However, the costs are expected to reduce due to various factors including intensive research & development of the drugs, production scales, and government grants & subsidies are expected to boost the visceral pain industry.
• The market came to witness significant gain, resulting in an increase in the collaboration within the pharmaceutical companies. Lack of awareness of the visceral pain treatments in the society is going to be a challenge for the growth of the market.
